The Presence of Multiple Prothrombotic Risk Factors Is Associated with a Higher Risk of Thrombosis in Individuals with Anticardiolipin Antibodies

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2385-2391

  Hudson, Marie ^b   Herr, Andrée Laure ^b   Rauch, Joyce ^b   Neville, Carolyn ^b   Chang, Erika ^a   Ibrahim, Reda ^b   Séguin, Chantal ^b   Kassis, Jeannine ^b   Busque, Lambert ^b   Fortin, Paul R ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NONE

Author keywords

Antibodies; Anticardiolipin; Factor V; Lupus coagulation inhibitor; Thrombophilia; Thrombosis

Indexed keywords

5 METHYLTETRAHYDROFOLATE REDUCTASE; 5 METHYLTETRAHYDROFOLIC ACID; ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; DIHYDROFOLATE REDUCTASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; LUPUS ANTICOAGULANT ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 0242693145     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
2. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-3.
3. Love PE, Santoro SA. Antiphospholipid antibodies; anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
4. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
5. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1-6.
6. Florell SR, Rodgers GM. Inherited thrombotic disorders: an update. Am J Hematol 1997;54:53-60.
7. Piette JC. Towards improved criteria for the antiphospholipid syndrome. Lupus 1998;7 Suppl 2:S149-S157.
8. Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999;84:59-70.
9. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. BMJ 1983;287:1021-3.
10. Loizou S, McCrea JD, Rudge AC. Measurement of anticardiolipin antibodies by enzyme-linked immunoadsorbent assay (ELISA). Standardization and quantitation of results. Clin Exp Immunol 1985;62:738-45.
11. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: B2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
12. Galli M, Comfurius P, Maassen C. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
13. Bevers EM, Galli M. Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Lancet 1990;336:952-3.
14. Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR. The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997;24:1545-51.
15. Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:1606-7.
16. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-32.
17. Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996;5:388-92.
18. Rauch J. Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Lupus 1998;7 Suppl 2:S29-S31.
19. Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998;80:936-41.
20. Galli M, Barbui T. Prothrombin as cofactor for antiphospholipids. Lupus 1998;7 Suppl 2:S37-S40.
21. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
22. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
23. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
24. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994;343:1535-6.
25. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat Genet 1995;10:111-3.
26. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF, The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997;77:818-21.
27. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11.
28. Margaglione M, D'Andrea G, d'Addedda M, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998;79:907-11.
29. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
30. Price BE, Rauch J, Shia MA, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996;157:2201-8.
31. The SAS System for Windows. Windows. Cary, North Carolina: The SAS Institute, 2002.
32. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986;146:2153-6.
33. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
34. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28:1660-5.
35. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74:1-9.
36. Escalante A, Brey RL, Mitchell BD, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995:98:559-65.
37. Lopez-Soto A, Cervera R, Font J, et al. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin Exp Rheumatol 1997;15:143-9.
38. Ginsberg JS, Demers C, Brill-Edwards P, et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995;98:379-83.
39. Seriolo B, Accardo S, Garnero A, Fasciolo D, Cutolo M. Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology Oxford 1999;38:675-8.
40. , Dizon-Townson D, Hutchison C, Silver R, Branch WD, Ward K. The Factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995;74:1029-31.
41. Chopra N, Koren S, Greer WL, et al. Factor V Leiden, prothrombin gene mutation and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 2002;29:1683-8.
42. Montaruli B, Borchiellini A, Tamponi G, et al. Factor V Arg506→Gln mutation in patients with antiphospholipid antibodies. Lupus 1996;5:303-6.
43. Ruiz-Arguelles GJ. Protein C resistance and antiphospholipid antibodies [letter]. Lupus 1996;5:633.
44. Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996;7:344-8.
45. Bentolila S, Ripoll L, Drouet L, Crassard I, Tournier-Lasserve E, Piette JC. Lack of association between thrombosis in primary antiphospholipid syndrome and the recently described thrombophilic 3′-untranslated prothrombin gene polymorphism. Thromb Haemost 1997;78:1415.
46. Bertolaccini ML, Atsumi T, Hunt BJ, Amengual O, Khamashta MA, Hughes GR. Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome. Thromb Haemost 1998;80:202-3.
47. Out HJ, de Groot PG, Hasselaar P, dan VM, Derksen RH. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1989;48:1023-8.
48. Cooper RC, Klemp P, Stipp CJ, Brink S. The relationship of anticardiolipin antibodies to disease activity in systemic lupus erythematosus. Br J Rheumatol 1989;28:379-82.
49. Koh KK, Home MK, III, Cannon RO, III. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 1999;82:626-33.